Review



anti mcl 1  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Santa Cruz Biotechnology anti mcl 1
    Anti Mcl 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 2246 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/Mcl-1+Antibody/pm41899524-104-25-28
    Average 96 stars, based on 2246 article reviews
    anti mcl 1 - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Nucleic Acid Electrophoresis:

    Article Title: The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models.
    Article Snippet: After drug treatment, cells were harvested in RIPA buffer (Cat. R0278, Sigma Aldrich, St. Louis, MO, USA) supplemented with protease (Cat. 78430, Thermo Fisher, Rockford, IL, USA) and phosphatase (Cat. 78428, Thermo Fisher, Rockford, IL, USA) inhibitors. .. Protein lysates were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to Immobilon®-P PVDF Membrane (PVDF) (Cat. IPVH00010, Merck Millipore, Darmstadt, Germany) for Western blot analysis using the following primary antibodies: BAX (cst-2772), GAPDH (cst-2118), cleaved caspase 3 (cst-9664) and PARP (cst-9542) from https://doi.org/10.3390/cells15020164 Cell Signaling Technology (Danvers, MA, USA) or cyclin A (sc-239), CDK2 (sc-6248) and Mcl-1 (sc-12756) from Santa Cruz Biotechnology (Paso Robles, CA, USA). .. Specific protein bands were visualized with Immobilon Western Chemiluminescent HRP Substrate (Cat. WBKLS0500, Merck Millipore, Darmstadt, Germany) and the Chemi Doc Imaging System (Bio-Rad, Hercules, CA, USA).

    Article Title: The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models
    Article Snippet: After drug treatment, cells were harvested in RIPA buffer (Cat. R0278, Sigma Aldrich, St. Louis, MO, USA) supplemented with protease (Cat. 78430, Thermo Fisher, Rockford, IL, USA) and phosphatase (Cat. 78428, Thermo Fisher, Rockford, IL, USA) inhibitors. .. Protein lysates were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to Immobilon ® -P PVDF Membrane (PVDF) (Cat. IPVH00010, Merck Millipore, Darmstadt, Germany) for Western blot analysis using the following primary antibodies: BAX (cst-2772), GAPDH (cst-2118), cleaved caspase 3 (cst-9664) and PARP (cst-9542) from Cell Signaling Technology (Danvers, MA, USA) or cyclin A (sc-239), CDK2 (sc-6248) and Mcl-1 (sc-12756) from Santa Cruz Biotechnology (Paso Robles, CA, USA). .. Specific protein bands were visualized with Immobilon Western Chemiluminescent HRP Substrate (Cat. WBKLS0500, Merck Millipore, Darmstadt, Germany) and the Chemi Doc Imaging System (Bio-Rad, Hercules, CA, USA).

    Membrane:

    Article Title: The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models.
    Article Snippet: After drug treatment, cells were harvested in RIPA buffer (Cat. R0278, Sigma Aldrich, St. Louis, MO, USA) supplemented with protease (Cat. 78430, Thermo Fisher, Rockford, IL, USA) and phosphatase (Cat. 78428, Thermo Fisher, Rockford, IL, USA) inhibitors. .. Protein lysates were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to Immobilon®-P PVDF Membrane (PVDF) (Cat. IPVH00010, Merck Millipore, Darmstadt, Germany) for Western blot analysis using the following primary antibodies: BAX (cst-2772), GAPDH (cst-2118), cleaved caspase 3 (cst-9664) and PARP (cst-9542) from https://doi.org/10.3390/cells15020164 Cell Signaling Technology (Danvers, MA, USA) or cyclin A (sc-239), CDK2 (sc-6248) and Mcl-1 (sc-12756) from Santa Cruz Biotechnology (Paso Robles, CA, USA). .. Specific protein bands were visualized with Immobilon Western Chemiluminescent HRP Substrate (Cat. WBKLS0500, Merck Millipore, Darmstadt, Germany) and the Chemi Doc Imaging System (Bio-Rad, Hercules, CA, USA).

    Article Title: The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models
    Article Snippet: After drug treatment, cells were harvested in RIPA buffer (Cat. R0278, Sigma Aldrich, St. Louis, MO, USA) supplemented with protease (Cat. 78430, Thermo Fisher, Rockford, IL, USA) and phosphatase (Cat. 78428, Thermo Fisher, Rockford, IL, USA) inhibitors. .. Protein lysates were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to Immobilon ® -P PVDF Membrane (PVDF) (Cat. IPVH00010, Merck Millipore, Darmstadt, Germany) for Western blot analysis using the following primary antibodies: BAX (cst-2772), GAPDH (cst-2118), cleaved caspase 3 (cst-9664) and PARP (cst-9542) from Cell Signaling Technology (Danvers, MA, USA) or cyclin A (sc-239), CDK2 (sc-6248) and Mcl-1 (sc-12756) from Santa Cruz Biotechnology (Paso Robles, CA, USA). .. Specific protein bands were visualized with Immobilon Western Chemiluminescent HRP Substrate (Cat. WBKLS0500, Merck Millipore, Darmstadt, Germany) and the Chemi Doc Imaging System (Bio-Rad, Hercules, CA, USA).

    Western Blot:

    Article Title: The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models.
    Article Snippet: After drug treatment, cells were harvested in RIPA buffer (Cat. R0278, Sigma Aldrich, St. Louis, MO, USA) supplemented with protease (Cat. 78430, Thermo Fisher, Rockford, IL, USA) and phosphatase (Cat. 78428, Thermo Fisher, Rockford, IL, USA) inhibitors. .. Protein lysates were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to Immobilon®-P PVDF Membrane (PVDF) (Cat. IPVH00010, Merck Millipore, Darmstadt, Germany) for Western blot analysis using the following primary antibodies: BAX (cst-2772), GAPDH (cst-2118), cleaved caspase 3 (cst-9664) and PARP (cst-9542) from https://doi.org/10.3390/cells15020164 Cell Signaling Technology (Danvers, MA, USA) or cyclin A (sc-239), CDK2 (sc-6248) and Mcl-1 (sc-12756) from Santa Cruz Biotechnology (Paso Robles, CA, USA). .. Specific protein bands were visualized with Immobilon Western Chemiluminescent HRP Substrate (Cat. WBKLS0500, Merck Millipore, Darmstadt, Germany) and the Chemi Doc Imaging System (Bio-Rad, Hercules, CA, USA).

    Article Title: The Synergistic Effects of rhArg with Bcl-2 Inhibitors or Metformin Co-Treatment in Multiple Cancer Cell Models
    Article Snippet: After drug treatment, cells were harvested in RIPA buffer (Cat. R0278, Sigma Aldrich, St. Louis, MO, USA) supplemented with protease (Cat. 78430, Thermo Fisher, Rockford, IL, USA) and phosphatase (Cat. 78428, Thermo Fisher, Rockford, IL, USA) inhibitors. .. Protein lysates were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to Immobilon ® -P PVDF Membrane (PVDF) (Cat. IPVH00010, Merck Millipore, Darmstadt, Germany) for Western blot analysis using the following primary antibodies: BAX (cst-2772), GAPDH (cst-2118), cleaved caspase 3 (cst-9664) and PARP (cst-9542) from Cell Signaling Technology (Danvers, MA, USA) or cyclin A (sc-239), CDK2 (sc-6248) and Mcl-1 (sc-12756) from Santa Cruz Biotechnology (Paso Robles, CA, USA). .. Specific protein bands were visualized with Immobilon Western Chemiluminescent HRP Substrate (Cat. WBKLS0500, Merck Millipore, Darmstadt, Germany) and the Chemi Doc Imaging System (Bio-Rad, Hercules, CA, USA).

    Article Title: Visomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML
    Article Snippet: N-acetylcysteine amide (NAC) was purchased from Sigma (Sigma, St. Louis, MO, United States; A9165). .. The following primary antibodies were used for western blots: Cyclin D1 (Santa Cruz Biotechnology, Dallas, TX, United States; sc-8396), CDK4 (Santa Cruz Biotechnology; sc-23896), p16 (Cell Signaling Technology, Danvers, MA, United States; 80772S), p21 (Cell Signaling Technology; 2947S), Rb (Santa Cruz Biotechnology; sc-102), Mcl-1 (Santa Cruz Biotechnology; sc-12756), Bcl-xl (eBioscience, Vienna, Austria; 14-6994-81), Bak (Santa Cruz Biotechnology; sc-832), Bax (Santa Cruz Biotechnology; sc-7480), P-ATM (Cell Signaling Technology; 5883S), P-Histone H2A.X (Cell Signaling Technology; 9718S), SYK (Santa Cruz Biotechnology; sc-1240), phospho-SYK (Cell Signaling Technology; 2710S), and β-actin (Santa Cruz Biotechnology; sc-4778). .. HRP-conjugated anti-rabbit and anti-mouse secondary antibodies were obtained from Bethyl Laboratories, Inc. (A120-101p and A90-116p-33; Montgomery, TX, United States).

    Incubation:

    Article Title: Targeting MCL1 by UMI-77 to induce mitophagy alleviates renal tubular epithelial cells injury in acute kidney injury.
    Article Snippet: .. After that the slides were incubated with primary antibodies against TOM20 (11802-1-AP, Proteintech), MCL-1 (sc-74437, Santa Cruz Biotechnology) and LAMP1 (sc-19992, Santa Cruz Biotechnology) at 4°C overnight, followed by incubation with fluorescence secondary antibodies. ..

    Fluorescence:

    Article Title: Targeting MCL1 by UMI-77 to induce mitophagy alleviates renal tubular epithelial cells injury in acute kidney injury.
    Article Snippet: .. After that the slides were incubated with primary antibodies against TOM20 (11802-1-AP, Proteintech), MCL-1 (sc-74437, Santa Cruz Biotechnology) and LAMP1 (sc-19992, Santa Cruz Biotechnology) at 4°C overnight, followed by incubation with fluorescence secondary antibodies. ..

    In Vitro:

    Article Title: Targeting MCL1 by UMI-77 to induce mitophagy alleviates renal tubular epithelial cells injury in acute kidney injury.
    Article Snippet: HK-2 cells were cultured in RPMI 1640 media (Sigma) supplemented with 10% fetal bovine serum (Gibco), 100 U/ ml penicillin, 100 μg/ml streptomycin under 5% CO2 at 37°C. .. HK-2 cells were subjected to 24 h of hypoxia followed by 3 h of reoxygenation to establish an in vitro hypoxia/reoxygenation (H/R) model. BeforeH/R, the siRNAs specific to MCL-1 (si-MCL-1) (sc-35877, Santa Cruz Biotechnology) were transfected into HK-2 cells to knock down MCL-1. .. The cell H/R model included various groups including Control, H/R, H/R+UMI-77, H/R+UMI-77+Mdivi-1, AR TIC LE IN PR ES S siControl (sc-37007, Santa Cruz Biotechnology) +H/R+UMI-77, siMCL-1+H/R+UMI-77.

    Article Title: Targeting MCL1 by UMI-77 to induce mitophagy alleviates renal tubular epithelial cells injury in acute kidney injury
    Article Snippet: HK-2 cells were cultured in RPMI 1640 media (Sigma) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin under 5% CO 2 at 37 °C. .. HK-2 cells were subjected to 24 h of hypoxia followed by 3 h of reoxygenation to establish an in vitro hypoxia/reoxygenation (H/R) model. Before H/R, the siRNAs specific to MCL-1 (si-MCL-1) (sc-35877, Santa Cruz Biotechnology) were transfected into HK-2 cells to knock down MCL-1. .. The cell H/R model included various groups including Control, H/R, H/R + UMI-77, H/R + UMI-77 + Mdivi-1, siControl (sc-37007, Santa Cruz Biotechnology) + H/R + UMI-77, siMCL-1 + H/R + UMI-77.

    Transfection:

    Article Title: Targeting MCL1 by UMI-77 to induce mitophagy alleviates renal tubular epithelial cells injury in acute kidney injury.
    Article Snippet: HK-2 cells were cultured in RPMI 1640 media (Sigma) supplemented with 10% fetal bovine serum (Gibco), 100 U/ ml penicillin, 100 μg/ml streptomycin under 5% CO2 at 37°C. .. HK-2 cells were subjected to 24 h of hypoxia followed by 3 h of reoxygenation to establish an in vitro hypoxia/reoxygenation (H/R) model. BeforeH/R, the siRNAs specific to MCL-1 (si-MCL-1) (sc-35877, Santa Cruz Biotechnology) were transfected into HK-2 cells to knock down MCL-1. .. The cell H/R model included various groups including Control, H/R, H/R+UMI-77, H/R+UMI-77+Mdivi-1, AR TIC LE IN PR ES S siControl (sc-37007, Santa Cruz Biotechnology) +H/R+UMI-77, siMCL-1+H/R+UMI-77.

    Article Title: Targeting MCL1 by UMI-77 to induce mitophagy alleviates renal tubular epithelial cells injury in acute kidney injury
    Article Snippet: HK-2 cells were cultured in RPMI 1640 media (Sigma) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin under 5% CO 2 at 37 °C. .. HK-2 cells were subjected to 24 h of hypoxia followed by 3 h of reoxygenation to establish an in vitro hypoxia/reoxygenation (H/R) model. Before H/R, the siRNAs specific to MCL-1 (si-MCL-1) (sc-35877, Santa Cruz Biotechnology) were transfected into HK-2 cells to knock down MCL-1. .. The cell H/R model included various groups including Control, H/R, H/R + UMI-77, H/R + UMI-77 + Mdivi-1, siControl (sc-37007, Santa Cruz Biotechnology) + H/R + UMI-77, siMCL-1 + H/R + UMI-77.

    Knockdown:

    Article Title: Targeting MCL1 by UMI-77 to induce mitophagy alleviates renal tubular epithelial cells injury in acute kidney injury.
    Article Snippet: HK-2 cells were cultured in RPMI 1640 media (Sigma) supplemented with 10% fetal bovine serum (Gibco), 100 U/ ml penicillin, 100 μg/ml streptomycin under 5% CO2 at 37°C. .. HK-2 cells were subjected to 24 h of hypoxia followed by 3 h of reoxygenation to establish an in vitro hypoxia/reoxygenation (H/R) model. BeforeH/R, the siRNAs specific to MCL-1 (si-MCL-1) (sc-35877, Santa Cruz Biotechnology) were transfected into HK-2 cells to knock down MCL-1. .. The cell H/R model included various groups including Control, H/R, H/R+UMI-77, H/R+UMI-77+Mdivi-1, AR TIC LE IN PR ES S siControl (sc-37007, Santa Cruz Biotechnology) +H/R+UMI-77, siMCL-1+H/R+UMI-77.

    Article Title: Targeting MCL1 by UMI-77 to induce mitophagy alleviates renal tubular epithelial cells injury in acute kidney injury
    Article Snippet: HK-2 cells were cultured in RPMI 1640 media (Sigma) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin under 5% CO 2 at 37 °C. .. HK-2 cells were subjected to 24 h of hypoxia followed by 3 h of reoxygenation to establish an in vitro hypoxia/reoxygenation (H/R) model. Before H/R, the siRNAs specific to MCL-1 (si-MCL-1) (sc-35877, Santa Cruz Biotechnology) were transfected into HK-2 cells to knock down MCL-1. .. The cell H/R model included various groups including Control, H/R, H/R + UMI-77, H/R + UMI-77 + Mdivi-1, siControl (sc-37007, Santa Cruz Biotechnology) + H/R + UMI-77, siMCL-1 + H/R + UMI-77.



    Similar Products

    94
    MedChemExpress protac mcl 1 degrader 1
    <t>PROTAC</t> <t>Mcl-1</t> <t>Degrader-1</t> reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.
    Protac Mcl 1 Degrader 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/PROTAC+Mcl1+degrader-1/pmc13407480-33-0-17
    Average 94 stars, based on 1 article reviews
    protac mcl 1 degrader 1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    ATCC mantle cell lymphoma mcl cell lines hbl 2
    <t>PROTAC</t> <t>Mcl-1</t> <t>Degrader-1</t> reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.
    Mantle Cell Lymphoma Mcl Cell Lines Hbl 2, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/REC-1/pm42864416-37-0-29
    Average 95 stars, based on 1 article reviews
    mantle cell lymphoma mcl cell lines hbl 2 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti mcl 1
    <t>PROTAC</t> <t>Mcl-1</t> <t>Degrader-1</t> reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.
    Anti Mcl 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/Mcl-1+Antibody/pm41762588-157-35-36
    Average 96 stars, based on 1 article reviews
    anti mcl 1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    ATCC human mcl cell lines jeko 1
    <t>PROTAC</t> <t>Mcl-1</t> <t>Degrader-1</t> reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.
    Human Mcl Cell Lines Jeko 1, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/JeKo-1/pm42265322-62-1-21
    Average 96 stars, based on 1 article reviews
    human mcl cell lines jeko 1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    MedChemExpress mcl 1 inhibitor
    <t>PROTAC</t> <t>Mcl-1</t> <t>Degrader-1</t> reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.
    Mcl 1 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/MIK665/pm42102807-323-26-29
    Average 94 stars, based on 1 article reviews
    mcl 1 inhibitor - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc mcl 1
    <t>PROTAC</t> <t>Mcl-1</t> <t>Degrader-1</t> reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.
    Mcl 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/Mcl-1+Rabbit+mAb/pm41932441-295-5-17
    Average 96 stars, based on 1 article reviews
    mcl 1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    86
    Mimetics mcl 1 specific bh3
    <t>PROTAC</t> <t>Mcl-1</t> <t>Degrader-1</t> reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.
    Mcl 1 Specific Bh3, supplied by Mimetics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/bh3+mimetics/pmc13118802-19-62-63
    Average 86 stars, based on 1 article reviews
    mcl 1 specific bh3 - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology anti mcl 1
    <t>PROTAC</t> <t>Mcl-1</t> <t>Degrader-1</t> reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.
    Anti Mcl 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/Mcl-1+Antibody/pm41899524-104-25-28
    Average 96 stars, based on 1 article reviews
    anti mcl 1 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc mcl
    <t>PROTAC</t> <t>Mcl-1</t> <t>Degrader-1</t> reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.
    Mcl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcl+1/Mcl-1+Antibody/pm41896944-68-16-20
    Average 96 stars, based on 1 article reviews
    mcl - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    PROTAC Mcl-1 Degrader-1 reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.

    Journal: Current Issues in Molecular Biology

    Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

    doi: 10.3390/cimb48070733

    Figure Lengend Snippet: PROTAC Mcl-1 Degrader-1 reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.

    Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

    Techniques: Western Blot

    PROTAC Mcl-1 Degrader-1 and Trametinib affect the proliferation of HT-29 and COLO-205 cells. ( A – C ) Simultaneous results obtained by Xcelligence Real-Time Proliferation assay after 48 h of treatment of HT-29 cells with ( A ) PROTAC Mcl-1 Degrader-1 and ( B ) Trametinib. Doses are represented by the same colors in the graph. ( D – F ) Proliferation results of COLO-205 cell line after 48 h of single and combined treatment with ( D ) PROTAC Mcl-1 Degrader-1 and ( E ) Trametinib, respectively. In combination, a dose of 1 µM Trametinib was used, and treatment was applied with variable doses of PROTAC Mcl-1 Degrader-1.

    Journal: Current Issues in Molecular Biology

    Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

    doi: 10.3390/cimb48070733

    Figure Lengend Snippet: PROTAC Mcl-1 Degrader-1 and Trametinib affect the proliferation of HT-29 and COLO-205 cells. ( A – C ) Simultaneous results obtained by Xcelligence Real-Time Proliferation assay after 48 h of treatment of HT-29 cells with ( A ) PROTAC Mcl-1 Degrader-1 and ( B ) Trametinib. Doses are represented by the same colors in the graph. ( D – F ) Proliferation results of COLO-205 cell line after 48 h of single and combined treatment with ( D ) PROTAC Mcl-1 Degrader-1 and ( E ) Trametinib, respectively. In combination, a dose of 1 µM Trametinib was used, and treatment was applied with variable doses of PROTAC Mcl-1 Degrader-1.

    Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

    Techniques: Proliferation Assay

    Effect of PROTAC Mcl-1 Degrader-1 on the migratory ability of colorectal cancer cells. ( A ) Wound healing assay was performed under a microscope (original magnification 4×) using an inverted microscope (500 µm scale bar) and images were taken at 0, 24 and 48 time intervals after treatment with different doses of PROTAC Mcl-1 Degrader-1 in HT-29 and ( B ) COLO-205 cell lines. ( C , D ) Wound closure analyses of HT-29 and COLO-205 cells were measured using PROTAC Mcl-1 Degrader-1 and microscopic images taken at 24 (black bars) and 48 (red bars) time intervals. Results are presented as mean ± standard deviation (n = 3/group). Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ** p < 0.01; ns = not significant.

    Journal: Current Issues in Molecular Biology

    Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

    doi: 10.3390/cimb48070733

    Figure Lengend Snippet: Effect of PROTAC Mcl-1 Degrader-1 on the migratory ability of colorectal cancer cells. ( A ) Wound healing assay was performed under a microscope (original magnification 4×) using an inverted microscope (500 µm scale bar) and images were taken at 0, 24 and 48 time intervals after treatment with different doses of PROTAC Mcl-1 Degrader-1 in HT-29 and ( B ) COLO-205 cell lines. ( C , D ) Wound closure analyses of HT-29 and COLO-205 cells were measured using PROTAC Mcl-1 Degrader-1 and microscopic images taken at 24 (black bars) and 48 (red bars) time intervals. Results are presented as mean ± standard deviation (n = 3/group). Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ** p < 0.01; ns = not significant.

    Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

    Techniques: Wound Healing Assay, Microscopy, Inverted Microscopy, Standard Deviation, Comparison, Software

    The combination of PROTAC Mcl-1 Degrader-1 and Trametinib did not lead to a statistically significant change in cell migration. ( A , B ) Colorectal cancer cells HT-29 and COLO-205 were treated with a combination of PROTAC Mcl-1 Degrader-1 and Trametinib. Trametinib dose was kept constant at 1 µM, while PROTAC Mcl-1 Degrader-1 doses were varied. Cell migration analysis was performed after treatment. Migration capabilities at 0, 24, and 48 h were visualized under a microscope. ( C , D ) Graphical analysis of wound closure was performed to determine the migratory ability of cells. The analysis was performed by comparing the 24 and 48 h treatments with the control group (ns = not significant).

    Journal: Current Issues in Molecular Biology

    Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

    doi: 10.3390/cimb48070733

    Figure Lengend Snippet: The combination of PROTAC Mcl-1 Degrader-1 and Trametinib did not lead to a statistically significant change in cell migration. ( A , B ) Colorectal cancer cells HT-29 and COLO-205 were treated with a combination of PROTAC Mcl-1 Degrader-1 and Trametinib. Trametinib dose was kept constant at 1 µM, while PROTAC Mcl-1 Degrader-1 doses were varied. Cell migration analysis was performed after treatment. Migration capabilities at 0, 24, and 48 h were visualized under a microscope. ( C , D ) Graphical analysis of wound closure was performed to determine the migratory ability of cells. The analysis was performed by comparing the 24 and 48 h treatments with the control group (ns = not significant).

    Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

    Techniques: Migration, Microscopy, Control

    Effect of PROTAC Mcl-1 Degrader-1 on cell count in colorectal cancer. ( A ) Flow cytometric analysis of the preservation of HT-29 and COLO-205 cell counts after 48 h of maintenance with PROTAC Mcl-1 Degrader-1 (n = 3). ( B , C ) Statistical analysis of the percentage cell counts of HT-29 and COLO-205 cells. Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ns = not significant.

    Journal: Current Issues in Molecular Biology

    Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

    doi: 10.3390/cimb48070733

    Figure Lengend Snippet: Effect of PROTAC Mcl-1 Degrader-1 on cell count in colorectal cancer. ( A ) Flow cytometric analysis of the preservation of HT-29 and COLO-205 cell counts after 48 h of maintenance with PROTAC Mcl-1 Degrader-1 (n = 3). ( B , C ) Statistical analysis of the percentage cell counts of HT-29 and COLO-205 cells. Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ns = not significant.

    Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

    Techniques: Cell Characterization, Preserving, Comparison, Software

    Combination treatment with PROTAC Mcl-1 Degrader-1 and Trametinib for 48 h showed a more pronounced effect on cell cycle distribution in HT-29 cells compared to COLO-205 cells. ( A ) A graph of the cell cycle percentage of HT-29 and COLO-205 cells was plotted after the combination. ( B , C ) As shown in the statistical analysis, an effect was observed in the S and G2/M phases in the HT-29 cell line, while no significant effect was statistically demonstrated in the COLO-205 cell line. Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ns = not significant.

    Journal: Current Issues in Molecular Biology

    Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

    doi: 10.3390/cimb48070733

    Figure Lengend Snippet: Combination treatment with PROTAC Mcl-1 Degrader-1 and Trametinib for 48 h showed a more pronounced effect on cell cycle distribution in HT-29 cells compared to COLO-205 cells. ( A ) A graph of the cell cycle percentage of HT-29 and COLO-205 cells was plotted after the combination. ( B , C ) As shown in the statistical analysis, an effect was observed in the S and G2/M phases in the HT-29 cell line, while no significant effect was statistically demonstrated in the COLO-205 cell line. Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ns = not significant.

    Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

    Techniques: Comparison, Software

    The combination of PROTAC Mcl-1 Degrader-1 and Trametinib affected mitochondrial membrane potential. ( A ) HT-29 and COLO-205 cell lines were stained with JC-1 after treatment with PROTAC Mcl-1 Degrader-1 for 48 h and imaged under a fluorescence microscope (original magnification 20×). The yellow-orange fluorescence of JC-1 dimers was found in cell regions with high mitochondrial membrane potential, while the green fluorescence of JC-monomers was prevalent in cell regions with low mitochondrial membrane potential. ( B , C ) Percentage red/green fluorescence intensity plots showed that HT-29 and COLO-205 cells were converted to MMP in both cell lines after 48 h of treatment with PROTAC Mcl-1 Degrader-1, particularly at the final dose of 10 μM. ( D ) Cell lines treated with a combination of PROTAC Mcl-1 Degrader-1 and Trametinib at different 48 h doses were subjected to JC-1 staining. After staining (original magnification 20×), images were acquired under a fluorescence microscope. ( E , F ) Quantitative analysis of the transition from mitochondrial orange to green coloration between different combination treatment groups. The statistical value of this experiment was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns = not significant.

    Journal: Current Issues in Molecular Biology

    Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

    doi: 10.3390/cimb48070733

    Figure Lengend Snippet: The combination of PROTAC Mcl-1 Degrader-1 and Trametinib affected mitochondrial membrane potential. ( A ) HT-29 and COLO-205 cell lines were stained with JC-1 after treatment with PROTAC Mcl-1 Degrader-1 for 48 h and imaged under a fluorescence microscope (original magnification 20×). The yellow-orange fluorescence of JC-1 dimers was found in cell regions with high mitochondrial membrane potential, while the green fluorescence of JC-monomers was prevalent in cell regions with low mitochondrial membrane potential. ( B , C ) Percentage red/green fluorescence intensity plots showed that HT-29 and COLO-205 cells were converted to MMP in both cell lines after 48 h of treatment with PROTAC Mcl-1 Degrader-1, particularly at the final dose of 10 μM. ( D ) Cell lines treated with a combination of PROTAC Mcl-1 Degrader-1 and Trametinib at different 48 h doses were subjected to JC-1 staining. After staining (original magnification 20×), images were acquired under a fluorescence microscope. ( E , F ) Quantitative analysis of the transition from mitochondrial orange to green coloration between different combination treatment groups. The statistical value of this experiment was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns = not significant.

    Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

    Techniques: Membrane, Staining, Fluorescence, Microscopy, Comparison, Software

    PROTAC Mcl-1 Degrader-1 alone was associated with a partial increase in apoptotic cell populations. (Q1 LL (Control), Q1 UL (Necrosis), Q1 UR (Late apoptosis), Q1 LR (Early apoptosis). ( A ) After 48 h of PROTAC Mcl-1 Degrader-1 treatment of HT-29 and COLO-205 cells, Annexin V and PI-labeled cell apoptosis was analyzed by flow cytometry. ( B , C ) Statistical analysis of cells in ( B ) early and ( C ) late apoptosis phases of HT-29 cell line after treatment with PROTAC Mcl-1 Degrader-1. ( D , E ) Statistical analysis of COLO-205 cells in ( D ) early and ( E ) late apoptosis phases after treatment with PROTAC Mcl-1 Degrader-1. The obtained results were presented using mean ± standard deviation (n = 3/group). Statistical significance in the experiment was determined using one-way ANOVA and Tukey’s test for multiple comparisons (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05.

    Journal: Current Issues in Molecular Biology

    Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

    doi: 10.3390/cimb48070733

    Figure Lengend Snippet: PROTAC Mcl-1 Degrader-1 alone was associated with a partial increase in apoptotic cell populations. (Q1 LL (Control), Q1 UL (Necrosis), Q1 UR (Late apoptosis), Q1 LR (Early apoptosis). ( A ) After 48 h of PROTAC Mcl-1 Degrader-1 treatment of HT-29 and COLO-205 cells, Annexin V and PI-labeled cell apoptosis was analyzed by flow cytometry. ( B , C ) Statistical analysis of cells in ( B ) early and ( C ) late apoptosis phases of HT-29 cell line after treatment with PROTAC Mcl-1 Degrader-1. ( D , E ) Statistical analysis of COLO-205 cells in ( D ) early and ( E ) late apoptosis phases after treatment with PROTAC Mcl-1 Degrader-1. The obtained results were presented using mean ± standard deviation (n = 3/group). Statistical significance in the experiment was determined using one-way ANOVA and Tukey’s test for multiple comparisons (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05.

    Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

    Techniques: Control, Labeling, Flow Cytometry, Standard Deviation, Software

    The combination of PROTAC Mcl-1 Degrader-1 and trametinib was observed to be associated with an increase in apoptotic cell populations. (Q1 LL (Control), Q1 UL (Necrosis), Q1 UR (Late apoptosis), Q1 LR (Early apoptosis). ( A ) The degree of apoptosis in HT-29 and COLO-205 cells was monitored by flow cytometry after 48 h of exposure to a combination of PROTAC Mcl-1 Degrader-1 and Trametinib. Combination therapy was shown to be associated with a higher level of apoptosis compared to monotherapy. ( B , C ) Treatment of the HT-29 cell line with the combination of PROTAC Mcl-1 Degrader-1 and Trametinib showed increased early and late apoptosis graphs, indicating the stages of apoptosis, compared to the control group. ( D , E ) The outcome of combination therapy in the COLO-205 cell line shows a significant effect on early apoptosis in the early and late apoptosis graphs. Statistical analysis after combination therapy showed that the final dose of 1 µm Trametinib and 10 µm PROTAC Mcl-1 Degrader-1 increased early apoptosis by 23% and late apotosis by 8%, particularly in the COLO-205 cell line. The values are expressed as the mean ± SD (n = 3/group). Statistical significance was determined using one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01; ns = not significant.

    Journal: Current Issues in Molecular Biology

    Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

    doi: 10.3390/cimb48070733

    Figure Lengend Snippet: The combination of PROTAC Mcl-1 Degrader-1 and trametinib was observed to be associated with an increase in apoptotic cell populations. (Q1 LL (Control), Q1 UL (Necrosis), Q1 UR (Late apoptosis), Q1 LR (Early apoptosis). ( A ) The degree of apoptosis in HT-29 and COLO-205 cells was monitored by flow cytometry after 48 h of exposure to a combination of PROTAC Mcl-1 Degrader-1 and Trametinib. Combination therapy was shown to be associated with a higher level of apoptosis compared to monotherapy. ( B , C ) Treatment of the HT-29 cell line with the combination of PROTAC Mcl-1 Degrader-1 and Trametinib showed increased early and late apoptosis graphs, indicating the stages of apoptosis, compared to the control group. ( D , E ) The outcome of combination therapy in the COLO-205 cell line shows a significant effect on early apoptosis in the early and late apoptosis graphs. Statistical analysis after combination therapy showed that the final dose of 1 µm Trametinib and 10 µm PROTAC Mcl-1 Degrader-1 increased early apoptosis by 23% and late apotosis by 8%, particularly in the COLO-205 cell line. The values are expressed as the mean ± SD (n = 3/group). Statistical significance was determined using one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01; ns = not significant.

    Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

    Techniques: Control, Flow Cytometry, Comparison